Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(26 sites)
United States
Stanford Neuromuscular Research, San Carlos, California University of Florida Clinical Research Center, Gainesville, Florida University of Kansas Medical Center, Fairway, Kansas Boston Children's Hospital, Boston, Massachusetts Washington University School of Medicine / St. Louis Children's Hospital, St Louis, Missouri Wake Forest Baptist Health, Winston-Salem, North Carolina University of Pennsylvania, Philadelphia, Pennsylvania Virginia Commonwealth University (Sanger Hall), Richmond, Virginia Australia
Wesley Research Institute, Auchenflower Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven Canada
Hopital de Chicoutimi, Chicoutimi Altasciences Montreal, Montreal McGIll University, Montreal University of Ottawa, Ottawa CHU Research Centre of Quebec, Québec France
Neuromuscular Reference Center Institute of Myology, Paris Germany
Ludwig Maximilians Universitaet Muenchen, München Italy
Centro Clinico NeMO, Milan Netherlands
Maastricht University Medical Center, Maastricht Spain
Hospital Universitario y Politécnico La Fe, Valencia United Kingdom
Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow Leonard Wolfson Experimental Neurology Centre CRF, London St. George's University Hospital, London Salford Royal Hospital, Salford Royal Hallamshire Hospital, Sheffield